BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Stein E, Sloan J, Sonu I, Kathpalia P, Jodorkovsky D. GERD for the nongastroenterologist: successful evaluation, management, and lifestyle-based symptom control. Ann N Y Acad Sci 2020;1482:106-12. [PMID: 32944973 DOI: 10.1111/nyas.14496] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Zhang M, Xu X, Liu W, Zhang Z, Cheng Q, Yang Z, Liu T, Liu Y, Ning Q, Chen T, Qi J. Proton Pump Inhibitor Therapy Increases the Risk of Spontaneous Bacterial Peritonitis in Patients with HBV-Related Acute-on-Chronic Liver Failure. Adv Ther 2021;38:4675-94. [PMID: 34308513 DOI: 10.1007/s12325-021-01844-1] [Reference Citation Analysis]
3 Wu X, Zhang D, Yu Y, Lou L, Li X. Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies. Biosci Rep 2020;40:BSR20193890. [PMID: 32406491 DOI: 10.1042/BSR20193890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Cholin L, Ashour T, Mehdi A, Taliercio JJ, Daou R, Arrigain S, Schold JD, Thomas G, Nally J, Nakhoul NL, Nakhoul GN. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression. BMC Nephrol 2021;22:264. [PMID: 34266395 DOI: 10.1186/s12882-021-02449-0] [Reference Citation Analysis]
5 Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [PMID: 32172363 DOI: 10.1007/s00228-020-02854-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tranah TH, Kronsten VT, Shawcross DL. Implications and Management of Cirrhosis-Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transpl 2021. [PMID: 34738724 DOI: 10.1002/lt.26353] [Reference Citation Analysis]
7 Ghoz H, Patel P, Stancampiano F, Patel S, Fox EA, Yousaf MB, Omer M, Heckman MG, Spiegel MR, Palmer WC. Proton-pump-inhibitor use associated with lower short-term rebleeding and mortality in patients receiving esophageal variceal band ligation: a retrospective cohort study. Eur J Gastroenterol Hepatol 2020;32:1571-8. [PMID: 32868651 DOI: 10.1097/MEG.0000000000001905] [Reference Citation Analysis]
8 Jacques ROC, Massignan LDS, Winkler MS, Balbinot RS, Balbinot SS, Soldera J. ACUTE-ON-CHRONIC LIVER FAILURE IS INDEPENDENTLY ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS. Arq Gastroenterol 2021;58:344-52. [PMID: 34705969 DOI: 10.1590/S0004-2803.202100000-58] [Reference Citation Analysis]
9 Kuo CJ, Lin CY, Chen CW, Hsu CY, Hsieh SY, Chiu CT, Lin WR. Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study. J Pers Med 2021;11:1063. [PMID: 34834415 DOI: 10.3390/jpm11111063] [Reference Citation Analysis]
10 Figueiredo LM, Rafael MA, Alexandrino G, Branco JC, Carvalho R, Costa MN, Martins A. Risk factors for the emergence of multidrug-resistant organisms in liver cirrhosis. Gastroenterol Hepatol 2021:S0210-5705(21)00163-1. [PMID: 34052400 DOI: 10.1016/j.gastrohep.2021.04.006] [Reference Citation Analysis]
11 Sun S, Ye W, Zhao R, Hu J, Zhang X, Yang M, Zhao H, Sheng J. Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study. Front Med (Lausanne) 2021;8:763370. [PMID: 34859015 DOI: 10.3389/fmed.2021.763370] [Reference Citation Analysis]
12 Terres AZ, Balbinot RS, Muscope ALF, Longen ML, Schena B, Cini BT, Luis Rost G Jr, Balensiefer JIL, Eberhardt LZ, Balbinot RA, Balbinot SS, Soldera J. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterol Hepatol 2021:S0210-5705(21)00086-8. [PMID: 33746028 DOI: 10.1016/j.gastrohep.2021.02.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun 2020;4:1562-77. [PMID: 33163829 DOI: 10.1002/hep4.1612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yokoyama K, Tsuchiya N, Yamauchi R, Miyayama T, Uchida Y, Shibata K, Fukuda H, Umeda K, Takata K, Tanaka T, Inomata S, Morihara D, Takeyama Y, Shakado S, Sakisaka S, Hirai F. Exploratory Research on the Relationship between Human Gut Microbiota and Portal Hypertension. Intern Med 2020;59:2089-94. [PMID: 32879200 DOI: 10.2169/internalmedicine.4628-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]